The advent of immunotherapy, particularly agents that inhibit the PD-1/PD-L1 pathway, has revolutionized treatment options for these patients, offering a more targeted approach that can enhance the immune system’s ability to combat cancer [60,61]. This evidence concerns the gene PDCD1 and cancer.